Oralair Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of seasonal allergic rhinitis, increased awareness of allergy immunotherapy benefits, clinical validation of grass pollen treatments, expansion of outpatient allergy clinics, improved diagnostic rates for pollen allergies.

The growth in the forecast period can be attributed to growing demand for disease-modifying allergy therapies, increasing adoption of personalized allergy treatments, expansion of immunotherapy use in pediatric populations, rising investments in allergy biologics research, broader reimbursement support for immunotherapy. Major trends in the forecast period include increasing adoption of sublingual immunotherapy, rising preference for long-term allergy desensitization treatments, growing use of standardized allergen extracts, expansion of preventive allergy management approaches, enhanced focus on patient adherence programs.

The rising prevalence of allergic conditions is expected to drive the growth of the Oralair market going forward. Allergic conditions occur when the immune system reacts to allergens, triggering symptoms such as itching, swelling, and inflammation. The increasing prevalence of these conditions is driven by factors including air pollution, environmental changes, and genetic predispositions. Oralair gradually desensitizes the immune system to allergens like grass pollen, reducing sensitivity over time, alleviating symptoms, and providing long-term relief from allergic reactions. For instance, in June 2023, according to the Department of Health, Victoria, an Australia-based state government agency, allergic diseases affect nearly 20% of Australia’s population, and projections suggest that by 2050, the patient population could increase by 70%, reaching approximately 7.7 million people. Therefore, the rising prevalence of allergic conditions is driving the growth of the Oralair market.

The increase in healthcare spending is expected to significantly propel the growth of the Oralair market. Healthcare spending refers to the allocation of financial resources for medical services, treatments, and related healthcare costs within a specific period. Factors such as aging populations, higher prevalence of chronic diseases, advancements in medical technology, and increasing demand for healthcare services contribute to rising healthcare spending. Higher investment in healthcare encourages patients and providers to seek long-term, cost-effective solutions, making Oralair a preferred option for managing allergic rhinitis. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based institute for health data, total health spending in Canada was projected to reach $344 billion in 2023, equating to $8,740 per person, representing a 2.8% increase from the previous year, which only grew 1.5% in 2022. Therefore, increasing healthcare spending is driving the growth of the Oralair market.

Growing awareness of immunotherapy is expected to further propel the growth of the Oralair market. Immunotherapy leverages the body’s immune system to treat diseases by enhancing or modifying immune responses. Rising demand for immunotherapy is driven by advancements in immune-based therapies, increased awareness of their effectiveness, and a shift toward personalized medicine. Oralair provides allergy immunotherapy that desensitizes the immune system to grass pollen, offering a targeted and lasting treatment for allergic rhinitis. For instance, in June 2025, the Cancer Research Institute, a US-based nonprofit focused on advancing immunotherapy research, reported that the US Food and Drug Administration approved 17 new immunotherapy treatments in 2024, marking an increase compared to previous years. Therefore, growing awareness of immunotherapy is driving the growth of the Oralair market.

Major companies operating in the oralair market are Stallergenes Greer.

Europe was the largest region in the oralair market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oralair market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oralair market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the oralair market by increasing costs related to imported allergen extracts, pharmaceutical excipients, packaging materials, and specialized manufacturing equipment. European and North American markets are most affected due to reliance on cross-border sourcing of standardized pollen allergens, while Asia-Pacific faces higher costs for finished-dose imports. These tariffs are contributing to price sensitivity among patients and healthcare providers. At the same time, they are encouraging regional allergen sourcing, localized tablet manufacturing, and supply chain diversification to improve long-term market stability.

The oralair market research report is one of a series of new reports that provides oralair market statistics, including oralair industry global market size, regional shares, competitors with a oralair market share, detailed oralair market segments, market trends and opportunities, and any further data you may need to thrive in the oralair industry. This oralair market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oralair is an allergy immunotherapy designed to treat grass pollen-induced allergic rhinitis, with or without conjunctivitis. It works by gradually desensitizing the immune system to grass pollen allergens, reducing the intensity of allergic reactions over time. Oralair provides a long-term approach to managing symptoms by exposing the body to controlled amounts of allergens, helping to effectively control grass pollen allergies.

The main types of indications for Oralair include allergic rhinitis, conjunctivitis, and allergic asthma. Allergic rhinitis is an inflammation of the nasal passages triggered by allergens, causing symptoms such as sneezing, congestion, and a runny nose. Oralair is distributed through multiple channels, including pharmacies, hospitals, clinics, and specialty clinics, and is used by various end users, including adults, adolescents, and children.

The oralair market consists of sales of allergen extracts and sublingual tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.